• The Commercial Trajectory of Anti-Fibrotic Agents (Nintedanib and Beyond): Analyzing 2026 Trends in Disease Modification (2025–2032)
    The global healthcare landscape is witnessing a significant shift toward specialized rare disease management. Scleroderma, a chronic autoimmune connective tissue disorder characterized by skin thickening and internal organ scarring, has become a focal point for pharmaceutical innovation. The Global Scleroderma Treatment Market is on a steady upward trajectory, driven by...
    0 Commentarii 0 Distribuiri 122 Views 0 previzualizare